Mesenchymal Stem Cell Composition for Osteoarthritis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, including autologous stem cell therapy, have limitations such as long wait times, invasive procedures, and limited effectiveness in improving quality of life, while allogeneic stem cell therapy only provides temporary relief from discomfort without significantly improving quality of life or cartilage regeneration.
Innovation Solution
A method involving the preparation of a composition comprising mesenchymal stem cells, extracellular vesicles, and growth factors, where mesenchymal stem cells are cultured in a keratinocyte serum-free medium supplemented with N-acetyl-L-cysteine and L-ascorbic acid 2-phosphate, and then allowed to stand for a predetermined time to produce extracellular vesicles and growth factors, which are used for intra-articular injection to treat osteoarthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous stem cell therapy is used to treat osteoarthritis, then the therapeutic effect is improved, but the treatment time and patient burden increase due to long wait times and invasive procedures
Solution Approach 1:
The patent applies preliminary action by pre-culturing and expanding mesenchymal stem cells in advance to create a ready-to-use cellular product. This allows the therapeutic cells to be prepared beforehand through controlled expansion in bioreactors, eliminating the need for time-consuming autologous cell collection and culture at the time of treatment, thus resolving the contradiction between therapeutic effectiveness and treatment time
Solution Approach 2:
The patent uses copying by creating allogeneic stem cell products that can serve as universal donors for multiple patients. Instead of requiring each patient's own cells (autologous), the invention uses cultured cells from healthy donors that can be expanded and distributed to treat multiple patients, significantly reducing treatment time while maintaining therapeutic benefits
2Ease of operation
If allogeneic stem cell therapy is used to treat osteoarthritis, then the treatment convenience is improved, but the quality of life improvement and cartilage regeneration are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the culture conditions and composition of the stem cell product. Specifically, the invention adjusts the culture medium composition, cell expansion parameters, and product formulation to enhance the therapeutic potency of allogeneic cells, enabling them to achieve significant quality of life improvement and cartilage regeneration while maintaining treatment convenience
Solution Approach 2:
The patent uses composite materials by combining mesenchymal stem cells with extracellular vesicles and growth factors in a unified therapeutic composition. This composite product enhances the overall therapeutic effect beyond what allogeneic cells alone can achieve, providing synergistic benefits for cartilage regeneration and quality of life improvement while maintaining the convenience of allogeneic therapy
3Quantity of substance
If traditional stem cell culture methods are used, then the cell expansion is achieved, but the production efficiency is low and the treatment availability is limited
Solution Approach 1:
The patent applies dynamics by transitioning from static traditional culture methods to dynamic bioreactor systems. The invention uses controlled agitation, aeration, and nutrient delivery in bioreactors to dramatically accelerate cell expansion kinetics, enabling high-density cell production with improved productivity and faster treatment availability
Solution Approach 2:
The patent applies preliminary action by establishing standardized cell expansion protocols and pre-manufacturing cellular products in advance. This allows for规模化 production of stem cells with optimized growth conditions predetermined, significantly improving production efficiency and making treatments more readily available to patients
Data Source
AI summary
The present disclosure provides a method for preparing a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors, the composition prepared by the method, and use of the composition for treating arthritis. The composition of the present disclosure achieves the effect of treating arthritis through various efficacy experiments.